THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year.

Compared to White men, Black men have a higher risk of developing prostate cancer. Additionally, Black men have a greater risk than White men of prostate cancer mortality. Asian men have a lower risk ...

For many men, a prostate cancer scare starts with one number. A PSA result comes back high, and ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

In a study involving more than 11,000 men enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial, about one quarter of elevated prostate-specific antigen (PSA) results ...

Employing MRI-targeted biopsy instead of systematic biopsy reduces overdiagnosis of low-grade prostate cancer by more than half, although diagnoses may be delayed among a small minority of patients ...

Elevated PSA with a negative biopsy What is the next step in the treatment of a patient who has a prostate-specific antigen (PSA) level between 4 and 10 ng/mL and a negative biopsy?— Jack W. Spitzberg ...